Mosaic ImmunoEngineering (CPMV) 10-Q 4 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 04, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	0-22182
Entity Registrant Name	MOSAIC IMMUNOENGINEERING, INC.
Entity Central Index Key	0000836564
Entity Tax Identification Number	84-1070278
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1537 South Novato Blvd
Entity Address, Address Line Two	#5
Entity Address, City or Town	Novato
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94947
City Area Code	(657)
Local Phone Number	208-0890
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,241,137

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 205,994	$ 226,142
Prepaid expenses and other current assets	17,157	43,352
Total current assets	223,151	269,494
Total assets	223,151	269,494
Current liabilities:
Accounts payable	123,889	113,513
Derivative liability	103,000	104,300
Accrued compensation	1,903,935	1,391,297
Accrued expenses and other	1,191,404	724,247
Total current liabilities	3,322,228	2,333,357
Convertible notes	1,156,048	735,148
Total liabilities	4,478,276	3,068,505
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.00001 par value: 100,000,000 shares authorized: 7,241,137 shares issued and outstanding	72	72
Additional paid-in capital	1,965,150	1,728,148
Accumulated deficit	(6,220,348)	(4,527,232)
Total stockholders’ deficit	(4,255,125)	(2,799,011)
Total liabilities and stockholders’ deficit	223,151	269,494
Series A Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	0	0
Series B Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	$ 1	$ 1

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	7,241,137	7,241,137
Common stock, shares outstanding	7,241,137	7,241,137
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized	630,000	630,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized	70,000	70,000
Preferred stock, shares issued	70,000	70,000
Preferred stock, shares outstanding	70,000	70,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 302,694	$ 376,767	$ 630,353	$ 622,915
General and administrative	581,032	533,935	982,409	1,092,235
Total operating expenses	883,726	910,702	1,612,762	1,715,150
Other income (expense):
Interest income	7	11	14	16
Change in valuation of derivative liability	800	(20,800)	1,300	(20,800)
Non-cash interest expense on convertible notes	(18,282)	(6,931)	(32,770)	(6,931)
Accretion to redemption value on convertible notes	(26,031)	(41,002)	(46,498)	(41,002)
Total other expense, net	(43,506)	(68,722)	(77,954)	(68,717)
Loss before income taxes	(927,232)	(979,424)	(1,690,716)	(1,783,867)
Provision for income taxes	2,400	0	2,400	2,400
Net loss	$ (929,632)	$ (979,424)	$ (1,693,116)	$ (1,786,267)
Basic loss per common share	$ (0.13)	$ (0.14)	$ (0.23)	$ (0.29)
Diluted loss per common share	$ (0.13)	$ (0.14)	$ (0.23)	$ (0.29)
Weighted average number of common shares outstanding – basic	7,235,447	7,222,403	7,235,447	6,228,900
Weighted average number of common shares outstanding – diluted	7,235,447	7,222,403	7,235,447	6,228,900

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Series A Convertible Voting Preferred Stock [Member]	Series B Convertible Voting Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 6	$ 1	$ 8	$ 420,198	$ (842,754)	$ (422,541)
Beginning balance, shares at Dec. 31, 2020	630,000	70,000	805,803
Conversion of Series A Convertible Voting Preferred Stock	$ (6)		$ 64	(58)
Conversion of Series A Convertible Voting Preferred Stock, shares	(630,000)		6,422,290
Share-based compensation				695,022		695,022
Net loss					(1,786,267)	(1,786,267)
Ending balance, value at Jun. 30, 2021		$ 1	$ 72	1,115,162	(2,629,021)	(1,513,786)
Ending balance, shares at Jun. 30, 2021		70,000	7,228,093
Beginning balance, value at Mar. 31, 2021		$ 1	$ 72	694,383	(1,649,597)	(955,141)
Beginning balance, shares at Mar. 31, 2021		70,000	7,228,093
Share-based compensation				420,779		420,779
Net loss					(979,424)	(979,424)
Ending balance, value at Jun. 30, 2021		$ 1	$ 72	1,115,162	(2,629,021)	(1,513,786)
Ending balance, shares at Jun. 30, 2021		70,000	7,228,093
Beginning balance, value at Dec. 31, 2021		$ 1	$ 72	1,728,148	(4,527,232)	(2,799,011)
Beginning balance, shares at Dec. 31, 2021		70,000	7,241,137
Share-based compensation				237,002		237,002
Net loss					(1,693,116)	(1,693,116)
Ending balance, value at Jun. 30, 2022		$ 1	$ 72	1,965,150	(6,220,348)	(4,255,125)
Ending balance, shares at Jun. 30, 2022		70,000	7,241,137
Beginning balance, value at Mar. 31, 2022		$ 1	$ 72	1,867,153	(5,290,716)	(3,423,490)
Beginning balance, shares at Mar. 31, 2022		70,000	7,241,137
Share-based compensation				97,997		97,997
Net loss					(929,632)	(929,632)
Ending balance, value at Jun. 30, 2022		$ 1	$ 72	$ 1,965,150	$ (6,220,348)	$ (4,255,125)
Ending balance, shares at Jun. 30, 2022		70,000	7,241,137

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities:
Net loss	$ (1,693,116)	$ (1,786,267)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	237,002	695,022
Change in fair value of derivative liability	(1,300)	20,800
Non-cash interest on convertible notes	32,770	6,931
Accretion to redemption value on convertible notes	46,498	41,002
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	26,195	31,324
Refundable income taxes	0	26,078
Accounts payable	10,376	(16,899)
Accrued compensation	512,638	458,147
Accrued expenses and other	467,157	200,788
Net cash used in operating activities	(361,780)	(323,074)
Investing activities:
Proceeds from dissolution of affiliate	0	27,637
Net cash provided by investing activities	0	27,637
Financing activities:
Proceeds from the issuance of convertible notes	341,632	525,003
Net cash provided by financing activities	341,632	525,003
Net change in cash and cash equivalents	(20,148)	229,566
Cash and cash equivalents, beginning of period	226,142	352,738
Cash and cash equivalents, end of period	205,994	582,304
Supplemental disclosure of non-cash financing activities:
Conversion of Series A Convertible Voting Preferred Stock to common stock:	0	64
Conversion of accrued payable to founder to convertible note	0	49,997
Supplemental disclosure of cash flow information:
Cash paid for income taxes	2,400	2,400
Cash paid for interest	$ 0	$ 0

Organization and Business

Organization and Business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	1. Organization and Business Organization Mosaic ImmunoEngineering, Inc. (the “Company,” “combined company,” “Mosaic,” “we,” “us,” or “our”), formerly known as Patriot Scientific Corporation, is a corporation organized under Delaware law on March 24, 1992. We are a development-stage biotechnology company focused on developing and eventually commercializing our proprietary immunomodulator platform technology. Our lead immunomodulator product candidate, MIE-101, is based on a naturally occurring plant virus known as Cowpea mosaic virus (or CPMV) which is believed to be non-infectious in humans and animals. However, because of its virus protein characteristics and genetic composition, CPMV elicits a strong immune response when delivered directly into tumors as shown in our preclinical studies. Data from numerous mouse cancer models and in companion dogs with naturally occurring tumors show the ability of intratumoral administration of CPMV to result in anti-tumor effects in treated tumors and systemically at other sites of disease through immune activation. MIE-101 is currently in late-stage preclinical development and our goal is to advance MIE-101 into veterinary studies and into Phase I clinical trials in 2023, provided we are able to raise sufficient funding. The Company has two wholly owned subsidiaries: Mosaic ImmunoEngineering Development Company (formerly referred to as Private Mosaic in connection with the reverse merger), a corporation organized under Delaware law on March 30, 2020 (date of inception) and Patriot Data Solutions Group, Inc., an inactive subsidiary of PTSC. Liquidity and Management’s Plans The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. At June 30, 2022, the Company had cash and cash equivalents of $ 205,994 There are a number of uncertainties associated with our ability to raise additional capital and we have no current arrangements with respect to any additional financing. In addition, the continuation of disruptions caused by COVID-19 may cause investors to slow down or delay their decision to deploy capital based on volatile market conditions which will adversely impact our ability to fund future operations. Consequently, there can be no assurance that any additional financing on commercially reasonable terms, or at all, will be available when needed. The inability to obtain additional capital will delay our ability to conduct our business operations. Any additional equity financing may involve substantial dilution to our then existing stockholders. The above matters raise substantial doubt regarding our ability to continue as a going concern.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	2. Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America. The accompanying unaudited condensed consolidated financial statements should therefore be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Certain reclassifications have been made to amounts in prior periods to conform to the current period presentation. All reclassifications have been applied consistently to the periods presented. Such reclassifications have no effect on net loss as previously reported. All intercompany transactions have been eliminated. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022 or any other period. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. In the opinion of management, the interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the results for the interim period presented. Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies during the three and six months ended June 30, 2022, as compared to the significant accounting policies disclosed in Note 2 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Recently Adopted Accounting Standards There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) during the three and six months ended June 30, 2022, as compared to the recent accounting pronouncements described in Note 2 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, that the Company believes are of significance or potential significance to the Company.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	3. Fair Value of Financial Instruments The Company’s financial instruments consist of money market funds as well as an anti-dilution issuance rights liability pursuant to the License Option Agreement with CWRU (see Note 6). The anti-dilution issuance rights meet the definition of a derivative under FASB’s Accounting Standards Codification (“ASC”) Topic 815, “Derivatives and Hedging”, and the liability is carried at fair value. Under this authoritative guidance, we are required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. We determine fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment or valuations by third-party professionals. The three levels of inputs that we may use to measure fair value are: · Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; · Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and · Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy at June 30, 2022 and December 31, 2021: Schedule of fair value of financial assets and liabilities Fair Value Measurements at June 30, 2022 Using Fair Value at Quoted Prices Significant Other Significant Assets: Cash and cash equivalents $ 205,994 $ 205,994 $ – $ – Total assets $ 205,994 $ 205,994 $ – $ – Liabilities: Anti-dilution issuance rights derivative liability $ 103,000 $ – $ – $ 103,000 Total liabilities $ 103,000 $ – $ – $ 103,000 Fair Value Measurements at December 31, 2021 Using Fair Value at Quoted Prices Significant Other Significant Assets: Cash and cash equivalents $ 226,142 $ 226,142 $ – $ – Total assets $ 226,142 $ 226,142 $ – $ – Liabilities: Anti-dilution issuance rights derivative liability $ 104,300 $ – $ – $ 104,300 Total liabilities $ 104,300 $ – $ – $ 104,300 Anti-Dilution Issuance Rights Derivative Liability Pursuant to the Series B Preferred Certificate of Designation, the Series B Preferred includes certain anti-dilution issuance rights, whereby the holder will continue to maintain equity ownership equal to 10% of the fully diluted shares of common stock outstanding, calculated on an as converted basis, including all other convertible securities outstanding and reserved for issuance (and excluding stock options issued and outstanding and reserved for issuance under a Board approved employee stock option plan reserving for issuance no more than ten percent (10%) of the outstanding common stock of the Company) until we raise approximately $626,000 from the sale of common or preferred stock, or a combination thereof. To determine the estimated fair value of the anti-dilution issuance rights liability, the Company used a Monte Carlo simulation methodology, which models the future movement of stock prices based on several key variables. At June 30, 2022 and December 31, 2021, the estimated fair value of the anti-dilution issuance rights was $ 103,000 104,300 The primary inputs used in valuing the anti-dilution issuance rights liability at June 30, 2022 and December 31, 2021 were as follows: Schedule of assumptions used June 30, 2022 December 31, 2021 Fair value of common stock (per share) $ 1.80 $ 1.02 Estimated additional shares of common stock 111,486 134,229 Expected volatility 115 105 Expected term (years) 0.50 0.25 Risk-free interest rate 2.51 0.06 The fair value of the common stock was determined by management with the assistance of an independent third-party specialist. The computation of expected volatility was estimated using available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. In addition, the Company incorporated the estimated number of shares, timing, and probability of future equity financings in the calculation of the anti-dilution issuance rights liability.

Investment in Affiliated Compan

Investment in Affiliated Companies	6 Months Ended
	Jun. 30, 2022
Investments in and Advances to Affiliates [Abstract]
Investment in Affiliated Companies	4. Investment in Affiliated Companies Phoenix Digital Solutions, LLC (“PDS”) PDS was formed by PTSC to pursue licensing of its intellectual property and we own 50 $ 27,637

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	5. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: Schedule of accrued expenses and other current liabilities June 30, 2022 December 31, 2021 Accrued consulting $ 667,738 $ 474,275 Crossflo acquisition liability 177,244 177,244 Accrued patent expenses 344,697 41,585 Other accrued expenses 1,725 31,143 Total accrued expenses and other current liabilities $ 1,191,404 $ 724,247 In September 2008, PTSC acquired Patriot Data Solutions Group, Inc. formerly known as Crossflo Systems, Inc. (“PDSG”). In connection with the acquisition of Crossflo by PTSC, we have accrued $ 177,244

License Agreements

License Agreements	6 Months Ended
	Jun. 30, 2022
License Agreements
License Agreements	6. License Agreements License Option and Agreement with CWRU On July 1, 2020, we signed a License Option Agreement with CWRU, granting the Company the exclusive right to license certain technology covering an immunomodulator platform technology to treat and prevent cancer and infectious diseases in humans and for veterinary use, including MIE-101, our lead clinical candidate. Under the License Option Agreement, CWRU granted the Company the exclusive option for a period of two (2) years to negotiate and enter into a license agreement with CWRU, provided that we meet certain diligence milestones. Under the License Option Agreement, Private Mosaic issued CWRU 70,000 shares of Class B Common Stock at the fair market value of $7 on the date of issuance, representing 10% of the fully diluted shares of common stock outstanding of Private Mosaic. On August 21, 2020, the Class B Stock was exchanged for shares of Series B Preferred, which included certain anti-dilution rights. Pursuant to the Certificate of Designation, the Series B Preferred holder will continue to maintain ownership equal to 10% of the fully diluted shares of common stock outstanding of the Company, including for such purposes all other convertible securities outstanding and reserved for issuance except stock options issued and outstanding and reserved for issuance under a board approved employee stock option plans reserving for issuance no more than ten percent (10%) of the outstanding common stock of the Company then outstanding, until we initially raise at least $1 million from the sale of either preferred or common stock, or a combination thereof (“Capital Threshold”). In addition, pursuant to the License Option Agreement, net working capital acquired under the reverse merger in August 2020 of approximately $374,000 was applied against the Capital Threshold. As of June 30, 2022, the remaining Capital Threshold was approximately $ 626,000 On May 4, 2022, we exercised our rights under the License Option Agreement and entered into a license agreement with CWRU (“License Agreement”). Pursuant to the terms of the License Agreement, we agreed to pay CWRU for each licensed product used in human applications (i) development milestones of up to $ 1.8 10,000 In addition, we are responsible for the reimbursement of all past, current and future patent fees incurred by CWRU under the License Agreement. During the three and six months ended June 30, 2022, we incurred $ 263,791 281,812 303,000 318,397 36,585 The License Agreement will remain in effect until the later of (i) twenty (20) years from the date of the License Agreement, (ii) on the expiration date of the last-to-expire patent under the License Agreement or (iii) at the expiry of all Market Exclusivity Periods for a licensed product. License Agreements with University of California San Diego (“UC San Diego”) During July 2021, we licensed the exclusive rights to develop and commercialize several novel vaccine candidates, including SARS-CoV-2 and other infectious disease applications from UC San Diego. Under the licensing agreement, we are obligated to pay (i) a nominal upfront license access fee, (ii) all patent costs incurred prior to the effective date of the license agreement, (iii) annual license maintenance fees, (iv) aggregate future milestone payments based on potential clinical development and regulatory milestones of up to $ 165,000 During September 2021, we licensed the exclusive rights from UC San Diego to develop and commercialize technology that involves the loading of immuno-stimulatory molecules into plant virus protein nanoparticles, including the ability to load these molecules into MIE-101, our lead product candidate. These plant virus protein nanoparticles can be loaded with other TLR agonists to further tailor specific immune response parameters. Under the licensing agreement, we are obligated to pay (i) a nominal upfront license access fee, (ii) all patent costs incurred prior to the effective date of the license agreement, (iii) annual license maintenance fees, (iv) aggregate future milestone payments based on potential clinical development and regulatory milestones of up to $ 1,250,000 For the three and six months ended June 30, 2022, we expensed $ 10,387 22,925 26,300 5,000

Convertible Notes

Convertible Notes	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Convertible Notes	7. Convertible Notes On May 7, 2021, we entered into a convertible note purchase agreement (“May Note Agreement”) with five (5) accredited investors, including three (3) members of our Board of Directors (“Board”) that participated on the same terms as other accredited investors. Pursuant to the Note Agreement, we received $ 525,003 49,997 575,000 On February 18, 2022, we entered into additional convertible note purchase agreements (“February Note Agreement”) with sixteen (16) accredited investors, including five (5) members of our Board that participated on the same terms as other accredited investors. Pursuant to the February Note Agreement, we received $ 341,632 341,632 The May and February Convertible Notes (collectively, the “Convertible Notes”) have no stated maturity date; bear interest at a simple rate equal to eight percent ( 8.0 18,282 32,770 The Convertible Notes will convert into the same equity securities offered in the Qualified Financing or Smaller Financing (“Conversion Shares”), as described below, at a conversion price equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing, or (ii) $2.377 for the May Convertible Notes (“May Conversion Price”) or $1.00 for the February Convertible Notes (“February Conversion Price”). Pursuant to the February Note Agreement, for each holder of the May Convertible Notes that purchased a February Convertible Note in the amount of (a) $50,000 or (b) an amount equivalent to the principal amount of their May Convertible Note, the conversion price of the May Convertible Notes was adjusted to the February Conversion Price. As of June 30, 2022, the principal amount of Convertible Notes that may be converted at the February Conversion Price was $866,632. In addition, the conversion price may be reduced or increased proportionately as a result of stock splits, stock dividends, recapitalizations, reorganizations, and similar transactions. Upon any conversion of the Convertible Notes in connection with a Qualified Financing or a Smaller Financing, as applicable, the Convertible Notes shall convert immediately prior to the closing thereof, such that the investors paying cash in such Qualified Financing or Smaller Financing, as applicable, are not diluted by the conversion of the Convertible Notes. Pursuant to the Convertible Notes, a Qualified Financing represents a single transaction or series of transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date (excluding proceeds from the issuance of any future convertible notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future convertible notes). In addition, in the event of a corporate transaction covering the sale of all or substantially all of the Company’s assets, or merger or consolidation with or into another entity, or change in ownership of at least 50% in voting securities of the Company, the holder of the Convertible Note may elect that either: (a) the Company pay the holder of such Convertible Note an amount equal to the sum of (i) all accrued and unpaid interest due on such Convertible Note and (ii) one and one-half (1.5) times the outstanding principal balance of such Convertible Note; or (b) such Convertible Note will convert into that number of conversion shares equal to the quotient obtained by dividing (i) the outstanding principal balance and unpaid accrued interest of such Convertible Note on the date of conversion by (ii) the May or February Conversion Price, as applicable. Pursuant to ASC Topic 835-30, “Imputation of Interest”, the Convertible Notes were initially recorded at their amortized cost of $ 916,632 1,145,790 26,031 46,498

Stockholders_ Equity and Share-

Stockholders’ Equity and Share-Based Compensation	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders’ Equity and Share-Based Compensation	8. Stockholders’ Equity and Share-Based Compensation Stockholders’ Equity The Company’s authorized capital consists of 100,000,000 shares of common stock, par value $0.00001 per share, and 5,000,000 shares of preferred stock, par value $0.00001 per share (“Preferred Stock”). Series A Preferred On August 21, 2020, the Company issued 630,000 shares of Series A Preferred (classified as permanent equity), in exchange for 630,000 shares of Class A Common Stock of Private Mosaic in connection with a reverse merger in August 2020. On January 29, 2021, 630,000 shares of Series A Preferred automatically converted into an aggregate 6,422,290 shares of common stock upon the effectiveness of a registration statement registering the resale of the underlying shares. The registration statement on Form S-3 was declared effective by the SEC on January 29, 2021. Series B Preferred On August 21, 2020, the Company issued 70,000 shares of Series B Preferred (classified as permanent equity), in exchange for 70,000 shares of Class B Common Stock of Private Mosaic in connection with a reverse merger in August 2020. Each share of Series B Preferred has a par value of $0.00001 per share, no dividend rate, a stated value of $6.50 per share, and each share of Series B Preferred initially converts into 11.46837 shares of common stock of the Company (“Series B Conversion Number”). In addition, the Series B Preferred possesses full voting rights, on an as-converted basis, as the common stock of the Company, as defined in the Series B Certificate of Designation. Furthermore, the Series B Preferred does not have any mandatory conversion rights and only converts upon written notice from the holder. The Series B Preferred also includes certain anti-dilution rights (“anti-dilution issuance rights”), whereby the holder of Series B Preferred will continue to maintain ownership equal to 10% of the fully diluted shares of common stock outstanding, including for such purposes all other convertible securities outstanding and reserved for issuance except equity awards issued and outstanding and reserved for issuance under a board approved equity compensation plan reserving for issuance no more than ten percent (10%) of the outstanding common stock of the Company then outstanding, until we raise at least $1 million from the sale of either preferred or common stock, or a combination thereof (“Capital Threshold”). In addition, pursuant to the License Option Agreement, net working capital acquired under the reverse merger in the amount of approximately $374,000 was applied against the Capital Threshold. The remaining Capital Threshold was approximately $626,000 as of June 30, 2022. The anti-dilution issuance rights meet the definition of a derivative instrument under FASB’s ASC Topic 815 (see Note 3). In the event of any Liquidation Event, the Holders of Series B Preferred shall be entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of common stock, an amount per share in cash equal to the greater of (x) the stated value of $6.50 for each share of Series B Preferred then held by the holder or (y) the amount payable per share of common stock which such holder of Series B Preferred would have received if such Holder had converted to common stock immediately prior to the Liquidation Event. Share-Based Compensation 2020 Omnibus Incentive Plan On October 21, 2020, we adopted our 2020 Omnibus Incentive Plan (the “2020 Plan”) and on October 22, 2020, the 2020 Plan was approved by our stockholders. The 2020 Plan was adopted to promote our long-term success and the creation of stockholder value by motivating participants, through equity incentive awards, to achieve long-term success in our business. The 2020 Plan permits the discretionary award of stock options, restricted stock, RSUs, and other equity awards to selected participants. On October 21, 2021, the first anniversary date from the adoption date of the 2020 Plan, the number of shares of common stock reserved for issuance under the 2020 Plan increased to 20% of the fully diluted shares of common stock outstanding, including shares of common stock reserved for issuance under convertible securities. As of June 30, 2022, we have reserved 1,661,966 541,957 1,106,965 The cost of all share-based awards will be recognized in the unaudited condensed consolidated financial statements based on the fair value of the awards. The fair value of stock option awards are determined using the Black-Scholes valuation model on the date of grant. The fair value of restricted stock awards and RSUs are equal to the closing market price of our common stock on the date of grant. The Company will generally recognize share-based compensation expense over the period of vesting or period that services will be provided for all time-based awards. Share-based compensation expense for the three and six months ended June 30, 2022 and 2021 was comprised of the following: Schedule of share-based compensation expense Three Months Ended Six Months Ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Research and development $ 29,894 $ 184,476 $ 101,544 $ 225,012 General and administrative 68,103 236,303 135,458 470,010 Total $ 97,997 $ 420,779 $ 237,002 $ 695,022 The following summarizes our transaction activity related to RSUs for the six months ended June 30, 2022: Schedule of RSU activity Shares Weighted Average Grant Date Fair Value Outstanding at January 1, 2022 505,192 $ 3.14 Granted 36,765 1.19 Vested – – Forfeited – – Outstanding at June 30, 2022 541,957 $ 3.01 As of June 30, 2022, the total estimated unrecognized compensation cost related to non-vested RSUs was approximately $ 84,000 0.41 13,044

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Legal Matters While the Company is not involved in any litigation as of June 30, 2022, the Company may be involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. Any litigation could have a material adverse effect on the Company’s business, financial condition, results of operations, and/or cash flows in the period in which the unfavorable outcome occurs or becomes probable, and potentially in future periods. Indemnification We have made certain guarantees and indemnities, under which we may be required to make payments to a guaranteed or indemnified party. We indemnify our directors, officers, employees, and agents to the maximum extent permitted under the laws of the State of Delaware. The duration of the guarantees and indemnities varies, and in many cases is indefinite. These guarantees and indemnities do not provide for any limitation of the maximum potential future payments we could be obligated to make. Historically, we have not been obligated to make any payments for these obligations and no liabilities have been recorded for these guarantees and indemnities in the accompanying unaudited condensed consolidated balance sheets. Escrow Shares On August 31, 2009, we gave notice to the former shareholders of Crossflo and Union Bank of California (the “Escrow Agent”) under Section 2.5 of the Agreement and Plan of Merger between us and Crossflo (the “Agreement”), outlining damages incurred by us in conjunction with the acquisition of Crossflo, and seeking the return of 5,690 shares of our common stock held by the Escrow Agent. Subsequently, former shareholders of Crossflo, representing a majority of the escrowed shares responded in protest to our claim, delaying the release of the escrowed shares until a formal resolution is reached. In the event we fail to prevail in our claim against the escrowed shares, we may be obligated to deposit into escrow approximately $256,000 of cash consideration due to the decline in our average stock price over the one-year escrow period calculated in accordance with Section 2.5 of the Agreement. We have evaluated the potential for loss regarding our claim and believe that it is probable that the resolution of this issue will not result in a material obligation to the Company, although there is no assurance of this. Accordingly, we have not recorded a liability for this matter.

Related Parties

Related Parties	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Parties	10. Related Parties During the period ended December 31, 2020, the Company’s Board of Directors approved to enter into consulting agreements with Nicole Steinmetz, Ph.D., acting Chief Scientific Officer, Jonathan Pokorski, Ph.D. (Dr. Steinmetz’s spouse), and Steve Fiering, Ph.D., each a co-founder of Private Mosaic and greater than 5% shareholder of the Company (“Related Parties”), for their scientific contributions towards advancing the technology platforms, in the monthly amounts of $ 5,000 2,500 2,500 30,000 30,000 187,000 137,500 In addition, on February 18, 2022, we entered into convertible note purchase agreements with sixteen (16) accredited investors, including five (5) members of our Board that participated on the same terms as other accredited investors, in the aggregate principal amount of $ 341,632 155,000

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events In February 2007, we invested an aggregate of $ 370,000 2,100,000 46 0.40 840,000 On July 6, 2022, we entered into a redemption agreement (the “Redemption Agreement”) with Holocom, pursuant to which we requested full redemption of our Series A Preferred Stock. Pursuant to the Redemption Agreement, we received cash proceeds in the amount of $ 336,000 840,000 Schedule of series A preferred stock to be redeemed over a period Period Shares of Series A Preferred Stock to be Redeemed each Month Monthly Redemption Proceeds to the Company Months 1-12 35,000 $14,000 Months 13-24 43,750 $17,500 Months 25-30 52,500 $21,000 Notwithstanding the foregoing, Holocom also agreed to expedite the redemption of the Series A Preferred Stock in the event that Holocom has excess cash on hand, which amount shall be calculated at each calendar month end period date (“Month End Date”), equal to an amount of (i) total cash on hand of Holocom and Scripps Ventures, Inc. (a related party entity of Holocom) (ii) less $ 200,000 The Redemption Agreement further provides that any amounts not paid within fifteen (15) days of its respective due date shall accrue interest at a rate of 8% per annum until fully paid and retroactively adjusted to 12% per annum from its original due date for amounts not paid within 90 days of its original due date. We have evaluated subsequent events after the consolidated balance sheet date and through the filing date of this Quarterly Report on Form 10-Q, and based on our evaluation, management has determined that no other subsequent events have occurred that would require recognition in the accompanying unaudited condensed consolidated financial statements or disclosure in the notes thereto other than as disclosed herein and in the accompanying notes.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America. The accompanying unaudited condensed consolidated financial statements should therefore be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Certain reclassifications have been made to amounts in prior periods to conform to the current period presentation. All reclassifications have been applied consistently to the periods presented. Such reclassifications have no effect on net loss as previously reported. All intercompany transactions have been eliminated. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022 or any other period. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. In the opinion of management, the interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the results for the interim period presented.
Significant Accounting Policies	Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies during the three and six months ended June 30, 2022, as compared to the significant accounting policies disclosed in Note 2 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) during the three and six months ended June 30, 2022, as compared to the recent accounting pronouncements described in Note 2 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, that the Company believes are of significance or potential significance to the Company.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of fair value of financial assets and liabilities	Schedule of fair value of financial assets and liabilities Fair Value Measurements at June 30, 2022 Using Fair Value at Quoted Prices Significant Other Significant Assets: Cash and cash equivalents $ 205,994 $ 205,994 $ – $ – Total assets $ 205,994 $ 205,994 $ – $ – Liabilities: Anti-dilution issuance rights derivative liability $ 103,000 $ – $ – $ 103,000 Total liabilities $ 103,000 $ – $ – $ 103,000 Fair Value Measurements at December 31, 2021 Using Fair Value at Quoted Prices Significant Other Significant Assets: Cash and cash equivalents $ 226,142 $ 226,142 $ – $ – Total assets $ 226,142 $ 226,142 $ – $ – Liabilities: Anti-dilution issuance rights derivative liability $ 104,300 $ – $ – $ 104,300 Total liabilities $ 104,300 $ – $ – $ 104,300
Schedule of assumptions used	Schedule of assumptions used June 30, 2022 December 31, 2021 Fair value of common stock (per share) $ 1.80 $ 1.02 Estimated additional shares of common stock 111,486 134,229 Expected volatility 115 105 Expected term (years) 0.50 0.25 Risk-free interest rate 2.51 0.06

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Schedule of accrued expenses and other current liabilities	Schedule of accrued expenses and other current liabilities June 30, 2022 December 31, 2021 Accrued consulting $ 667,738 $ 474,275 Crossflo acquisition liability 177,244 177,244 Accrued patent expenses 344,697 41,585 Other accrued expenses 1,725 31,143 Total accrued expenses and other current liabilities $ 1,191,404 $ 724,247

Stockholders_ Equity and Shar_2

Stockholders’ Equity and Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of share-based compensation expense	Schedule of share-based compensation expense Three Months Ended Six Months Ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Research and development $ 29,894 $ 184,476 $ 101,544 $ 225,012 General and administrative 68,103 236,303 135,458 470,010 Total $ 97,997 $ 420,779 $ 237,002 $ 695,022
Schedule of RSU activity	Schedule of RSU activity Shares Weighted Average Grant Date Fair Value Outstanding at January 1, 2022 505,192 $ 3.14 Granted 36,765 1.19 Vested – – Forfeited – – Outstanding at June 30, 2022 541,957 $ 3.01

Subsequent Events (Tables)

Subsequent Events (Tables)	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Schedule of series A preferred stock to be redeemed over a period	Schedule of series A preferred stock to be redeemed over a period Period Shares of Series A Preferred Stock to be Redeemed each Month Monthly Redemption Proceeds to the Company Months 1-12 35,000 $14,000 Months 13-24 43,750 $17,500 Months 25-30 52,500 $21,000

Organization and Business (Deta

Organization and Business (Details Narrative) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 205,994	$ 226,142

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details - Fair Value) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	$ 205,994	$ 226,142
Fair value of liabilities	103,000	104,300
Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	205,994	226,142
Fair value of liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	0	0
Fair value of liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	0	0
Fair value of liabilities	103,000	104,300
Cash and Cash Equivalents [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	205,994	226,142
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	205,994	226,142
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	0	0
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	0	0
Antidilution Issuance Rights Liability [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of liabilities	103,000	104,300
Antidilution Issuance Rights Liability [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of liabilities	0	0
Antidilution Issuance Rights Liability [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of liabilities	0	0
Antidilution Issuance Rights Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of liabilities	$ 103,000	$ 104,300

Fair Value of Financial Instr_4

Fair Value of Financial Instruments (Details - Assumption) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair value of common stock (per share)	$ 1.80	$ 1.02
Estimated additional shares of common stock	111,486	134,229
Expected volatility	115%	105%
Expected term (years)	6 months	3 months
Risk-free interest rate	2.51%	0.06%

Fair Value of Financial Instr_5

Fair Value of Financial Instruments (Details Narrative) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Derivative liability	$ 103,000	$ 104,300

Investment in Affiliated Comp_2

Investment in Affiliated Companies (Details Narrative) - USD ($)	1 Months Ended
	Jan. 31, 2021	Jun. 30, 2022
PDS [Member]
Schedule of Investments [Line Items]
Investment in affiliated company	$ 27,637
PDS [Member]
Schedule of Investments [Line Items]
Equity interest percentage		50%

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued consulting	$ 667,738	$ 474,275
Crossflo acquisition liability	177,244	177,244
Accrued patent expenses	344,697	41,585
Other accrued expenses	1,725	31,143
Total accrued expenses and other current liabilities	$ 1,191,404	$ 724,247

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities (Details Narrative)	Jun. 30, 2022 USD ($)
Crossflo Investors [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Possible account payable	$ 177,244

License Agreements (Details Nar

License Agreements (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	May 04, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Offsetting Assets [Line Items]
General and administrative expense		$ 581,032	$ 533,935	$ 982,409	$ 1,092,235
CWRU [Member]
Offsetting Assets [Line Items]
Regulatory milestones	$ 1,800,000
Royalty	$ 10,000
U C San Diego [Member]
Offsetting Assets [Line Items]
Regulatory milestones				165,000
General and administrative expense		10,387		22,925
Immuno Stimulatory [Member]
Offsetting Assets [Line Items]
Regulatory milestones				1,250,000
License Option Agreement [Member]
Offsetting Assets [Line Items]
Capital threshold remaining		626,000		626,000
License Option Agreement [Member] | General and Administrative Expense [Member]
Offsetting Assets [Line Items]
Patent legal fees		263,791		281,812
Accrued patent costs		303,000		303,000
License Option Agreement [Member] | CWRU [Member]
Offsetting Assets [Line Items]
Accrued patent fees		318,397		318,397		$ 36,585
License Agreements [Member] | U C San Diego [Member]
Offsetting Assets [Line Items]
Accrued patent fees		$ 26,300		$ 26,300		$ 5,000

Convertible Notes (Details Narr

Convertible Notes (Details Narrative) - USD ($)			3 Months Ended		6 Months Ended
	Feb. 18, 2022	May 07, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Debt Instrument [Line Items]
Proceeds from convertible debt					$ 341,632	$ 525,003
Non-cash interest expense on Convertible Notes			$ 18,282	$ 6,931	32,770	6,931
Convertible notes payable amortized cost basis			916,632		916,632
Redemption value			1,145,790		1,145,790
Accretion to Redemption Value			26,031	$ 41,002	$ 46,498	$ 41,002
May Note Agreement [Member]
Debt Instrument [Line Items]
Proceeds from convertible debt		$ 525,003
Principal amount		575,000
May Note Agreeement [Member]
Debt Instrument [Line Items]
Accrued payable		$ 49,997
February Note Agreement [Member]
Debt Instrument [Line Items]
Proceeds from issuance of unsecured debt	$ 341,632
Convertible Notes Payable	$ 341,632
Convertible Notes [Member]
Debt Instrument [Line Items]
Interest					8%
Non-cash interest expense on Convertible Notes			18,282		$ 32,770
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Accretion to Redemption Value			$ 26,031		$ 46,498

Stockholders' Equity and Share-

Stockholders' Equity and Share-Based Compensation (Details - Share Based Compensation) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based compensation expense	$ 97,997	$ 420,779	$ 237,002	$ 695,022
Research and Development Expense [Member]
Share-based compensation expense	29,894	184,476	101,544	225,012
General and Administrative Expense [Member]
Share-based compensation expense	$ 68,103	$ 236,303	$ 135,458	$ 470,010

Stockholders' Equity and Shar_2

Stockholders' Equity and Share-Based Compensation (Details - RSU activity) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, Beginning | shares	505,192
Weighted Average Exercise Price Outstanding, Beginning | $ / shares	$ 3.14
Number of Options Granted | shares	36,765
Weighted Average Exercise Price Granted | $ / shares	$ 1.19
Number of Options Vested | shares	0
Weighted Average Exercise Price Vested | $ / shares	$ 0
Number of Options Forfeited | shares	0
Weighted Average Exercise Price Forfeited | $ / shares	$ 0
Number of Options Outstanding, Ending | shares	541,957
Weighted Average Exercise Price Outstanding, Ending | $ / shares	$ 3.01

Stockholders_ Equity and Shar_3

Stockholders’ Equity and Share-Based Compensation (Details Narrative)	6 Months Ended	20 Months Ended
	Jun. 30, 2022 USD ($) shares	Jun. 30, 2022 USD ($) shares
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost | $	$ 84,000	$ 84,000
Weighted average vesting period	4 months 28 days
2020 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock for reserved for Issuance	1,661,966	1,661,966
2020 Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock for reserved for Issuance	541,957	541,957
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period		13,044
2020 Plan [Member] | Share Based Awards [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock for reserved for Issuance	1,106,965	1,106,965

Related Parties (Details Narrat

Related Parties (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Feb. 18, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Research and development expenses	$ 302,694	$ 376,767	$ 630,353	$ 622,915
Accrued consulting fees	187,000		187,000			$ 137,500
February Note Agreement [Member]
Related Party Transaction [Line Items]
Convertible Notes Payable					$ 341,632
February Note Agreement [Member] | Five Board Members [Member]
Related Party Transaction [Line Items]
Convertible Notes Payable					$ 155,000
Consulting Agreements [Member]
Related Party Transaction [Line Items]
Research and development expenses	$ 30,000	$ 30,000
Nicole Steinmetz [Member]
Related Party Transaction [Line Items]
Related party expenses			5,000
Steinmetzs Spouse [Member]
Related Party Transaction [Line Items]
Related party expenses			2,500
Steve Fiering [Member]
Related Party Transaction [Line Items]
Related party expenses			$ 2,500

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - Series A Preferred Stock [Member]	Aug. 01, 2022 USD ($) shares
Months 1 To 12 [Member]
Subsequent Event [Line Items]
Preferred stock redeemed | shares	35,000
Proceed from redemption | $	$ 14,000
Months 13 To 24 [Member]
Subsequent Event [Line Items]
Preferred stock redeemed | shares	43,750
Proceed from redemption | $	$ 17,500
Months 25 To 30 [Member]
Subsequent Event [Line Items]
Preferred stock redeemed | shares	52,500
Proceed from redemption | $	$ 21,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Holocom Inc [Member] - USD ($)		1 Months Ended
	Jul. 06, 2022	Feb. 28, 2007
Subsequent Event [Line Items]
Invested value		$ 370,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Excess capital	$ 200,000
Subsequent Event [Member] | Redemption Agreement [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Trust Preferred Securities	$ 336,000
Stock Redeemed or Called During Period, Shares	840,000
Series A Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Number of shares exchange		2,100,000
Ownership interest		46%
Redemption price		$ 0.40
Redemption value		$ 840,000